Archive · 22 Sep 2026
ChrysCapital expects pharma to lead latest $2.2 billion fund
ChrysCapital is an investment firm that recently raised a $2.2 billion fund.
It expects about 20% to 25% of the fund to go into medicines and healthcare companies.
The firm has usually bought smaller ownership stakes, but it recently bought control of Novartis India.
Novartis India is bringing its sales and distribution work inside the company.
It is also adding medicine brands to grow its business.
ChrysCapital especially likes companies making medicines for long-term illnesses.
It is more careful about companies that depend heavily on selling generic medicines in the United States.
The firm also sees opportunities because many Indian drug companies may merge or be sold.
It expects companies to improve profits through acquisitions and better operations as industry growth slows.
ChrysCapital expects pharmaceuticals and healthcare to receive 20%-25% of its latest $2.2 billion fund.
The firm’s majority acquisition of Novartis India marks its move into control investing after years of minority investments.
Novartis India is restructuring to bring sales and distribution in-house and has added several brands.
ChrysCapital favors domestic formulations, especially chronic-therapy companies, while remaining cautious on US-focused generics.
The firm expects pharmaceutical consolidation and deal opportunities to continue as growth slows and valuations vary.
- Who
- ChrysCapital, led in the article by executive Sheth, and Novartis India.
- What
- ChrysCapital expects pharmaceuticals and healthcare to account for 20%-25% of its latest $2.2 billion fund and is expanding into control investments.
- When
- The investment strategy and market trends were described in the article; the fund’s investment period is not specified.
- Where
- India, including the Indian pharmaceutical market.
- Why
- ChrysCapital sees growth, brand potential, consolidation, and valuation opportunities in Indian pharmaceuticals, while remaining cautious about regulatory and pricing risks.
Investment opportunities
Investment risks
Domestic formulations
Investment opportunities
ChrysCapital sees potential in domestic formulation companies, particularly those focused on chronic therapies, strong brands, organic growth, and acquisitions.
Investment risks
The firm says growth in pharmaceuticals has slowed from roughly 15%-16% historically to about 9%-10%, making passive investment less suitable.
Export formulations
Investment opportunities
Indian pharmaceutical companies can access international customers and markets through export formulations and related capabilities.
Investment risks
ChrysCapital is cautious about businesses dependent on the United States generic-drug market because of price erosion, United States Food and Drug Administration inspections, and tariffs.
Active ownership and consolidation
Investment opportunities
Control deals, mergers, margin improvement, and industry consolidation could help unlock value and create new transactions.
Investment risks
Some opportunities involve restructuring and execution risk, while API businesses have faced a difficult pricing cycle and recent performance has been tepid, despite some signs of improvement.
- Latest fund
- $2.2 billion
- Expected pharma and healthcare allocation
- 20%-25%
- Indian domestic pharmaceutical market
- Around $60 billion in FY26, projected to reach $130 billion by 2030
- Novartis India revenue
- Approximately ₹450 crore
- Typical ChrysCapital target revenue
- Around ₹1,000 crore
- Recent annual PE investment in Indian pharma
- Estimated at $1.2-$1.3 billion, up from around $800-$900 million
- Indian pharma and medical-device PE/VC investment since 2016
- $16.4 billion across 303 deals, according to EY data